Coherus Oncology nears October CVR distribution
Alpha Vantage · AD HOC NEWS · · AI-summarised by FinFlash
Coherus Oncology is approaching a Contingent Value Rights distribution on October 7, 2026, payable to shareholders of record as of September 30, 2026, following the sale process of its biosimilar assets. The company reported improved second-quarter 2026 revenues and narrowed losses, though uncertainty remains over CVR proceeds and cash burn. Analysts maintain a Buy rating with a price target well above the current Nasdaq price, reflecting oncology growth potential alongside inherent risks.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.